Published in J Nippon Med Sch on June 01, 2005
Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev (2009) 1.90
Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res (2007) 1.31
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal (2009) 1.25
Role of decorin in the antimyeloma effects of osteoblasts. Blood (2008) 1.19
Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma (2010) 0.93
Lumican reduces tumor growth via induction of fas-mediated endothelial cell apoptosis. Cancer Microenviron (2010) 0.92
Quantitative proteomics analysis by isobaric tags for relative and absolute quantitation identified Lumican as a potential marker for acute aortic dissection. J Biomed Biotechnol (2011) 0.89
The Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle. Front Oncol (2015) 0.81
Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Clin Cancer Res (2016) 0.79
Lumican as a novel potential clinical indicator for acute aortic dissection: A comparative study, based on multi-slice computed tomography angiography. Exp Ther Med (2016) 0.78
Lumican overexpression exacerbates lipopolysaccharide-induced renal injury in mice. Mol Med Rep (2015) 0.75
A Time-Based and Intratumoral Proteomic Assessment of a Recurrent Glioblastoma Multiforme. Front Oncol (2016) 0.75
Asporin enhances colorectal cancer metastasis through activating the EGFR/src/cortactin signaling pathway. Oncotarget (2016) 0.75
Extracellular Matrix, a Hard Player in Angiogenesis. Int J Mol Sci (2016) 0.75